IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
Saphris
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Wed, 8 Sep 2010 08:44:19 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (16 lines) 
Merck Receives Approval from FDA for Expanded Indications for 
Atypical Antipsychotic Medication Saphris

 From the PharmaLive.com News Archive - Sep. 07, 2010

Merck today announced that the FDA has approved two sNDA's for 
Saphris  (asenapine) sublingual tablets to expand the product's 
indications. Saphris is now indicated for the treatment of 
schizophrenia in adults, as monotherapy for the acute treatment of 
manic or mixed episodes associated with bipolar I disorder in adults, 
and as adjunctive therapy with either lithium or valproate for the 
acute treatment of manic or mixed episodes associated with bipolar I 
disorder in adults.

www.peoplewho.org

ATOM RSS1 RSS2